PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
100.00%
Revenue growth of 100.00% while XRF.AX is flat. Bruce Berkowitz would check if a small edge can widen further.
-45.66%
Negative gross profit growth while XRF.AX is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-92.42%
Negative EBIT growth while XRF.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-92.42%
Negative operating income growth while XRF.AX is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
100.00%
Net income growth of 100.00% while XRF.AX is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
200.00%
EPS growth of 200.00% while XRF.AX is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
50.00%
Diluted EPS growth of 50.00% while XRF.AX is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
2.52%
Share change of 2.52% while XRF.AX is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
2.52%
Diluted share change of 2.52% while XRF.AX is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative OCF growth while XRF.AX is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-100.00%
Negative FCF growth while XRF.AX is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
131.31%
10Y revenue/share CAGR at 75-90% of XRF.AX's 174.48%. Bill Ackman would press for new markets or product lines to narrow the gap.
329.11%
5Y revenue/share CAGR above 1.5x XRF.AX's 75.74%. David Dodd would look for consistent product or market expansions fueling outperformance.
39.95%
3Y revenue/share CAGR above 1.5x XRF.AX's 23.27%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-102513.07%
Negative 10Y OCF/share CAGR while XRF.AX stands at 80.61%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-807.57%
Negative 5Y OCF/share CAGR while XRF.AX is at 232.50%. Joel Greenblatt would question the firm’s operational model or cost structure.
-188.10%
Negative 3Y OCF/share CAGR while XRF.AX stands at 34.74%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
24856.74%
Net income/share CAGR above 1.5x XRF.AX's 194.47% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
1928.87%
5Y net income/share CAGR above 1.5x XRF.AX's 657.02%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-26.66%
Negative 3Y CAGR while XRF.AX is 159.12%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
94.41%
5Y equity/share CAGR above 1.5x XRF.AX's 31.16%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
52.28%
3Y equity/share CAGR above 1.5x XRF.AX's 22.72%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.46%
We have a declining book value while XRF.AX shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
8.96%
Debt growth of 8.96% while XRF.AX is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
-32.55%
We cut SG&A while XRF.AX invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.